Analyst: No Novo-loss in China
A change in the Danish reimbursement-rules for Novo Nordisk’s diabetes drugs will, according to analysts, not have consequences for the company’s growth on the Chinese market, as Novo Nordisk initially feared in connection with the re-evaluation proposal.
Novo Nordisk will most likely not lose sales in China in the event of a Danish re-evaluation of reimbursements for the company’s diabetes drugs Victoza and Levemir, which will only be given conditional reimbursements if the proposal is approved.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Sanofi: We will definitely make an objection
For abonnenter
Novo: reimbursement-changes will have consequences
For abonnenter
